Press Releases

Historic SomaLogic Press Releases >

Date	Title and Summary	Additional Formats
Apr 02, 2020	Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia SOUTH SAN FRANCISCO, Calif. , April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm ® CyTOF ® technology was used in a clinical study
Mar 16, 2020	Consortium of Medical Schools Led by Mount Sinai Fast-Tracking COVID-19 Detection Test Utilizing Fluidigm Microfluidics Technology Speed and scale of Fluidigm microfluidics technology to facilitate early-stage host monitoring for COVID-19 SOUTH SAN FRANCISCO, Calif. , March 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Mar 11, 2020	Fluidigm and SIgN Establish the First Center of Excellence in Singapore to Advance Imaging Mass Cytometry Fluidigm’s First Mass Cytometry Center of Excellence in Singapore and Southeast Asia for Advancement of Highly Multiplexed Tissue Imaging in Translational and Clinical Research SOUTH SAN FRANCISCO, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative
Mar 10, 2020	Fluidigm Introduces AccuLift Laser Capture Microdissection System to Advance Translational and Clinical Pathology Research Driving Cell Capture to Insight with Precision, Speed and Simplicity to Accelerate Biomarker and Therapeutic Development SOUTH SAN FRANCISCO, Calif. , March 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life
Mar 03, 2020	Fluidigm and Next Gen Diagnostics Enter into Agreement to Improve the Efficiency of Pathogen Sample Preparation for Microbial Whole Genome Sequencing Enabling Low-Cost, High-Volume Sequencing of Drug-Resistant Pathogens for Hospital Infection Control and Surveillance SOUTH SAN FRANCISCO, Calif. and HINXTON, United Kingdom , March 03, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an industry leader in microfluidics technology, and
Feb 26, 2020	Fluidigm Completes Acquisition of InstruNor AS Acquisition to expand Fluidigm’s industry-leading mass cytometry capabilities and address flow cytometry markets with the addition of fully automated sample prep SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools
Feb 12, 2020	Fluidigm to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that Chris Linthwaite , President and Chief Executive Officer, will
Feb 10, 2020	Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million ; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates potential clinical value of using Imaging Mass Cytometry Covance selects Fluidigm CyTOF technology to
Feb 10, 2020	Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry New Center of Excellence to Advance Highly Multiplexed Tissue Imaging in Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Feb 10, 2020	Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life sciences company, has selected Fluidigm’s CyTOF® technology and the industry-leading Maxpar® Direct™